



UNITED STATES PATENT AND TRADEMARK OFFICE

cm
UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER FOR PATENTS
P.O. Box 1450
Alexandria, Virginia 22313-1450
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/517,210	03/09/2005	Evvy Lundgren-Akerlund	10142.0004	4342

22852 7590 11/02/2006

FINNEGAN, HENDERSON, FARABOW, GARRETT & DUNNER
LLP
901 NEW YORK AVENUE, NW
WASHINGTON, DC 20001-4413

EXAMINER

HADDAD, MAHER M

ART UNIT	PAPER NUMBER
----------	--------------

1644

DATE MAILED: 11/02/2006

Please find below and/or attached an Office communication concerning this application or proceeding.

Office Action Summary

Application No.

10/517,210

Applicant(s)

LUNDGREN-AKERLUND, EVY

Examiner

Maher M. Haddad

Art Unit

1644

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☐ Responsive to communication(s) filed on ____.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-18 is/are pending in the application.
- 4a) Of the above claim(s) ____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) ____ is/are allowed.
- 6) ☐ Claim(s) ____ is/are rejected.
- 7) ☐ Claim(s) ____ is/are objected to.
- 8) ☒ Claim(s) 1-18 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on ____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
2. ☐ Certified copies of the priority documents have been received in Application No. ____.
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).
- * See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date ____.
- 4) ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date. ____.
- 5) ☐ Notice of Informal Patent Application
- 6) ☐ Other: ____.

DETAILED ACTION

1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:

- I. Claims 4 and 6, drawn to a method of identifying a mammalian mesenchymal stem cell using a marker comprising an integrin alpha 10 chain expressed on the cell surface of a mesenchymal stem cell or intracellular in mesenchymal stem cell as a marker for mammalian mesenchymal stem cells, wherein the expression is detected by *an immunoassay*, classified in Class 435, subclass 7.1.
- II. Claims 4 and 6, drawn to a method of identifying a mammalian mesenchymal stem cell using a marker comprising an integrin alpha 10 chain and alpha 11 expressed on the cell surface of a mesenchymal stem cell or intracellular in mesenchymal stem cell as a marker for mammalian mesenchymal stem cells, wherein the expression is detected by *an immunoassay*, classified in Class 435, subclass 7.1
- III. Claim 5, drawn to a method of identifying a mammalian mesenchymal stem cell using a marker comprising an integrin alpha 10 chain expressed on the cell surface of a mesenchymal stem cell or intracellular in mesenchymal stem cell as a marker for mammalian mesenchymal stem cells, wherein the expression is detected by *mRNA*, classified in Class 435, subclass 6.
- IV. Claim 5, drawn to a method of identifying a mammalian mesenchymal stem cell using a marker comprising an integrin alpha 10 chain and alpha 11 chain expressed on the cell surface of a mesenchymal stem cell or intracellular in mesenchymal stem cell as a marker for mammalian mesenchymal stem cells, wherein the expression is detected by *mRNA*, classified in Class 435, subclass 6.
- V. Claims 7-8, drawn to a method for determining whether a test compound modulates a mammalian mesenchymal stem cell differentiation the method comprising providing a mesenchymal stem cell that expresses integrin alpha 10 with a test compound; classified in Class 435, subclass 7.1.
- VI. Claims 7-8, drawn to a method for determining whether a test compound modulates a mammalian mesenchymal stem cell differentiation the method comprising providing a mesenchymal stem cell that expresses integrin alpha 10 and alpha 11 chain with a test compound; classified in Class 435, subclass 7.1.
- VII. Claims 9-11 and 17, drawn to a method for producing an isolated population of mammalian cells enriched for mesenchymal stem cells relative a reference population, the method comprising providing at least a portion of a population of cells comprising mesenchymal stem cell with a compound, classified in Class 435, subclass 7.1.

Art Unit: 1644

- VIII. Claims 12-14 and 18, drawn to an enriched mammalian cellular population of mesenchymal stem cells, comprising a mesenchymal stem cell that expresses an integrin alpha 10 chain or alpha 10 chain and alpha 11 chain, classified in Class 435, subclass 334.
- IX. Claim 16, drawn to a method for modulating differentiation of a mammalian mesenchymal stem cell, comprising utilizing a marker comprising an integrin alpha 10 chain or an integrin alpha 10 chain and an integrin alpha 11 chain expressed on the cell surface of mesenchymal stem cell or intracellular in a mesenchymal stem cell, classified in Class 435, subclass 7.1

Claims 1-3 and 15 link inventions I-IV. The restriction requirement among the linked inventions is subject to the nonallowance of the linking claims 1-3 and 15. Upon the allowance of the linking claims, the restriction requirement as to the linked inventions shall be withdrawn and any claims depending from or otherwise including all the limitations of the allowable linking claims will be entitled to examination in the instant application. Applicants are advised that if any such claims depending from or including all the limitations of the allowable linking claims are presented in a continuation or divisional application, the claims of the continuation or divisional application may be subject to provisional statutory and/or nonstatutory double patenting rejections over the claims of the instant application. Where a restriction requirement is withdrawn, the provisions of 35 U.S.C. 121 are no longer applicable. *In re Ziegler*, 44 F.2d 1211, 1215, 170 USPQ 129, 131-32 (CCPA 1971). See also MPEP § 804.01.

2. Groups I-VII and IX are different methods. Method of identifying, methods of determining, methods of producing and a method of modulating differ with respect to ingredients, method steps, and endpoints; therefore, each method is patentably distinct.

3. These inventions are distinct for the reasons given above. In addition, they have acquired a separate status in the art as shown by different classification and/or recognized divergent subject matter. Further, even though in some cases the classification is shared, a different field of search would be required based upon the structurally distinct products recited and the various methods of use comprising distinct method steps. Therefore restriction for examination purposes as indicated is proper. Further, a prior art search also requires a literature search. It is an undue burden for the examiner to search more than one invention.

4. Applicant is advised that the response to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed.

5. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the


Art Unit: 1644

application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

6. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maher Haddad whose telephone number is (571) 272-0845. The examiner can normally be reached Monday through Friday from 7:30 am to 4:00 pm. A message may be left on the examiner's voice mail service. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christina Chan can be reached on (571) 272-0841. The fax number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

October 24, 2006


Maher Haddad, Ph.D.
Primary Examiner
Technology Center 1600